223 related articles for article (PubMed ID: 37758237)
21. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
Yu B; Liu D
J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
[TBL] [Abstract][Full Text] [Related]
23. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
24. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract][Full Text] [Related]
25. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Crit Rev Oncol Hematol; 2023 Dec; 192():104189. PubMed ID: 37866413
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
Dias E Silva D; Andriatte GM; Pestana RC
Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
[TBL] [Abstract][Full Text] [Related]
28. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
29. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D
Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
[TBL] [Abstract][Full Text] [Related]
30. Antibody-drug conjugates: in search of partners of choice.
Fuentes-Antrás J; Genta S; Vijenthira A; Siu LL
Trends Cancer; 2023 Apr; 9(4):339-354. PubMed ID: 36746689
[TBL] [Abstract][Full Text] [Related]
31. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
32. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions.
High P; Carmon KS
Cancer Lett; 2023 Jun; 564():216191. PubMed ID: 37100113
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for Antibody-Drug Conjugates in Solid Tumors.
Katrini J; Boldrini L; Santoro C; Valenza C; Trapani D; Curigliano G
Mol Cancer Ther; 2024 Apr; 23(4):436-446. PubMed ID: 38363729
[TBL] [Abstract][Full Text] [Related]
34. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
36. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies.
Xie H; Adjei AA
J Thorac Oncol; 2019 Mar; 14(3):358-376. PubMed ID: 30599202
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
Mjaess G; Aoun F; Rassy E; Diamand R; Albisinni S; Roumeguère T
Clin Genitourin Cancer; 2023 Feb; 21(1):171-174. PubMed ID: 35999150
[TBL] [Abstract][Full Text] [Related]
38. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S; Naidoo J
Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates in hematologic malignancies.
Leslie LA; Younes A
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
[TBL] [Abstract][Full Text] [Related]
40. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
